Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I Clinical Study in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer. (B003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03953833
Recruitment Status : Not yet recruiting
First Posted : May 17, 2019
Last Update Posted : May 17, 2019
Sponsor:
Collaborator:
Shanghai Jiaolian Medicine Research and Development Co., Ltd.
Information provided by (Responsible Party):
Shanghai Pharmaceuticals Holding Co., Ltd

Brief Summary:

Indications: HER2-positive breast cancer. Experimental popular topic: Phase I clinical study of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MCC-DM1 Conjugate for Injection Subject: Phase I clinical trial on the safety, tolerability, pharmacokinetics of B003 in the treatment of HER2-positive recurrent or metastatic breast cancer.Drug Name : Recombinant Humanized Anti-HER2 Monoclonal Antibody-MCC-DM1 Conjugate for Injection R & D code: B003 Drug Type : Biological Products

Test purpose:

Main objective: To assess the safety and tolerability characteristics of B003 in HER2-positive patients with recurrent or metastatic breast cancer. The dose-limiting toxicity (DLT) is assessed and the maximum tolerated dose (MTD) is explored.

Secondary objective: To evaluate the pharmacokinetics,immunogenicity and preliminary efficacy of B003 conjugate in patients with HER2-positive recurrent or metastatic breast cancer and explore the recommended doses for further study.


Condition or disease Intervention/treatment Phase
HER2-positive Breast Cancer Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003. Phase 1

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Intervention Model: Single Group Assignment
Intervention Model Description:

The study is divided into the dose escalation group and the dose expansion group. Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is from day 1 to day 21 of the first treatment cycle.

Dose expansion stage: treatment cycle is administered every 21days and could be administered continuously until the disease progresses or is intolerable.DLT is not accessed during this stage.

Blind method: open Test range: Domestic test

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Clinical Trial on the Safety, Tolerability, Pharmacokinetics of B003 in the Treatment of HER2-positive Recurrent or Metastatic Breast Cancer.
Estimated Study Start Date : May 28, 2019
Estimated Primary Completion Date : March 31, 2020
Estimated Study Completion Date : April 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: recombinant anti-HER2 humanized monoclonal antibody conjugate
Drug Name : Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection R & D code: B003 Drug Type : Biological Products
Biological: Recombinant anti-HER2 humanized monoclonal antibody conjugate for injection.R&D code: B003.

Usage: Intravenous infusion; Dose escalation stage: doses 0.6, 1.2, 2.4, 3.6, 4.8 mg / kg, 1-6subjects each. Dose expansion stage: 20 subjects are enrolled and take the recommended dose based on the result of dose escalation stage.

Infusion time:90 minutes(90min-106min suggested) for the first time; if no infusion reaction happens, the follow-up time is adjusted to at least30 minutes(30min-40min suggested).Dose escalation stage: treatment cycle is administered every 21days,the infusion is taken at the first day of each treatment cycle.Observation period of DLT is the 21st day of the first treatment cycle.





Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: through study completion, an average of 2 years ]
    The maximum tolerated dose (MTD) is operationally defined in toxicology as the highest daily dose of a chemical that does not cause overt toxicity in subjects

  2. Dose-Limiting Toxicity [ Time Frame: From day 1 to day 21 of treatment ]
    Some of the major toxic side effects are the main reasons limiting the continued increase in the dose of chemotherapy drugs, which are the dose-limiting toxicity of chemotherapy drugs.

  3. Immunogenicity assessment [ Time Frame: through study completion, an average of 2 years ]
    Sample positive rate and Individual positive rate of Anti-drug antibody(ADA)

  4. Titer of ADA positive sample [ Time Frame: through study completion, an average of 2 years ]
    a test to determine the level or degree of ADA positive samples and analyse the effect on the plasma concentration.

  5. Pharmacokinetics measurement A [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    Peak Plasma Time (Tmax)


  6. Pharmacokinetics measurement B [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    Peak Plasma Concentration (Cmax)


  7. Pharmacokinetics measurement C [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    half-life time


  8. Pharmacokinetics measurement D [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    Mean Residence Time( MRT)


  9. Pharmacokinetics measurement E [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    Area under the plasma concentration versus time curve (AUC)


  10. Pharmacokinetics measurement F [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    elimination rate constant


  11. Pharmacokinetics measurement G [ Time Frame: through study completion, an average of 2 year ]

    According to the detection of the serum concentration of B003 in plasma sample, the diagram of drug concentration-time for individual and each dose group could be concluded.

    clearance rate(CL/F)


  12. Therapeutic Efficacy A [ Time Frame: from date of start from the infusion of the first subject until the date after two treatments of the last subject, assessed up to 14 months. ]
    Objective Remission Rate (ORR): to be defined as the percentage of patients with complete response or partial response. Patients with CR or PR for the first evaluation will be confirmed after 4weeks. Patients without any evaluations are regarded as none-response.

  13. Therapeutic Efficacy B [ Time Frame: from date of start from the infusion of the first subject until the date after two treatments of the last subject, assessed up to 14 months. ]
    Disease Control rate(DCR): to be defined as the percentage of patients with complete response, partial response or stable disease.

  14. Therapeutic Efficacy C [ Time Frame: from the date when he patient has CR or PR to the first evaluation until the date when the patient has disease progression or death, assessed up to 14 months. ]
    Duration of response(DOR): to be defined as the duration from the first evaluation time when the patient has CR or PR to the first evaluation time when the patient has disease progression or death.

  15. Therapeutic Efficacy D [ Time Frame: from the date when he patient has CR or PR to the first evaluation until the date when the patient has disease progression or death, assessed up to 14 months. ]
    Progression-free survival:to be defined as the duration from the time of first infusion to the first recording time when the patient has disease progression or death.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years old ≤ age ≤ 75 years old, female;
  • Histological or cytologically confirmed recurrent or metastatic breast cancer,Anti-HER2 treatment failure for recurrent or metastatic disease;1) A retrograde or metastatic breast cancer diagnosed as HER2 positive (FISH positive and / or immuno-histochemistry (IHC) 3+) by the Department of Pathology diagnosis;
  • According to RECIST v 1.1, patients with measurable and/or unmeasurable lesions: 1) Patients with bone metastases, as long as the bone metastases have never received radiotherapy, and the primary tumours are available for HER2 detection and Biomarker analysis, which can be enrolled.
  • Female patients of childbearing age, patients and/or their partners should agree to use a highly effective non-hormonal contraceptive method or two effective non-hormonal contraceptive methods. Continue to use the appropriate contraceptive measures during the study period and at least 6 months after the last dose.
  • Electrocorticography (ECOG) physical state (PS) is 0-1 points;
  • Expected to survive for more than 3 months;
  • Understand and voluntarily sign the informed consent form.

Exclusion Criteria:

  • Previously received T-DM1 or same type of drug for treatment, previously used trastuzumab within 3 months before the trial, previously involved in other clinical trials within 4 weeks before the trial.
  • Known to be allergic to the study drug or its components;
  • Have received any anti-cancer trial medication within 28 days prior to the start of the trial;
  • Have received hormone treatment within 7 days before the trial.
  • Hematological toxicity caused by previous treatment CTCAE ≥ 2 persistence (except hemoglobin) (NCI-CTCAE version 4.03);
  • A third gap effusion with clinical symptoms that cannot be controlled by drainage or other methods.
  • The cumulative dose of anthracyclines used meets the following values: doxorubicin or liposomal doxorubicin >450 mg/m2; epirubicin >900 mg/m2; mitoxantrone >120 mg/m2; Idarubicin > 90 mg/m2. If another anthracycline or more than one anthracycline is used, the cumulative dose should not exceed the equivalent dose of doxorubicin 500mg/m2
  • Patients with other malignant tumors (cervical cancer of StageI B or lower that has been cured, non-invasive basal cells or squamous cell skin cancer, complete remission (CR) > 10 years of malignant melanoma, Except for other malignant tumors with complete remission (CR) > 5 years);
  • Laboratory abnormalities:

    1. Neutrophil count <1.5×109/L
    2. Platelet count <100×109/L
    3. Hemoglobin <90 g/L
    4. Total bilirubin > 1.5 x upper limit of normal (ULN)
    5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 × ULN
    6. Serum creatinine >1.5×ULN or creatinine clearance <50 mL/min;
  • Currently suffering from a serious and uncontrollable systemic disease (eg, clinically significant cardiovascular disease, lung disease, active infection, or metabolic disease);
  • Have a tendency to hemorrhage and thrombosis:

    1. Any CTCAE 4.03 Level 2 bleeding event occurred within 2 months prior to screening, or CTCAE 4.03 Level 3 and above bleeding events within the first 6 months of screening;
    2. A history of gastrointestinal bleeding within 6 months prior to screening or a clear tendency to gastrointestinal bleeding. Such as: esophageal varices with bleeding risk, local active ulcer lesions, fecal occult blood + +;
    3. There is currently active bleeding or coagulopathy (PT>16s, activated partial thromboplastin time >43s, thrombin time)>21s, INR≥2.3, all of which need to be ruled out), have bleeding tendency or are receiving thrombolysis or anti- Coagulation therapy
    4. Patients need anticoagulant therapy with warfarin or heparin;
    5. Patients need long-term antiplatelet therapy (eg aspirin, clopidogrel);
    6. Thrombotic or embolic events in the past 6 months, such as: cerebrovascular accidents (including transient ischemic attacks), pulmonary embolism;
  • History of severe cardiovascular disease:

    1. According to NYHA (New York Heart Association), current cardiac function classification: grade III or IV;
    2. There is currently congestive heart failure and New York Heart Association cardiac function grade II and above;
    3. A history of unstable angina or myocardial infarction within 6 months prior to screening;
    4. There are currently arrhythmias requiring therapeutic intervention (patients taking beta-blockers or digoxin can be enrolled);
    5. According to the current two-dimensional echocardiographic results, the left ventricular ejection fraction (LVEF) is <50%;
    6. Have a history of LVEF falling below 40%, or have had symptomatic congestive heart failure when treated with anti-HER2;
    7. There is currently poorly controlled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg);
    8. Cardiac troponin I ≥ 0.2 ng/mL.
  • There is a history of moderate or severe dyspnea at rest due to advanced malignancies or their complications or severe pulmonary primary disease, or current continuous oxygen therapy is required;
  • Symptomatic brain metastases, depression or schizophrenia;
  • History of immunodeficiency, including: HIV-positive, or other acquired, congenital immunodeficiency disease, or a history of organ transplantation;
  • Hepatitis B (HBsAg and / or HBcAb positive, and peripheral blood hepatitis B virus DNA titer test results beyond the normal range of the research center), and / or hepatitis C patients;
  • Alcohol dependence, hormone dependence or drug abusers;
  • The investigator believes that there are other factors that are not suitable for the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03953833


Contacts
Layout table for location contacts
Contact: Dake Li, Project Manager +86-021-61871700 ext 8258 lidk@sphchina.com

Sponsors and Collaborators
Shanghai Pharmaceuticals Holding Co., Ltd
Shanghai Jiaolian Medicine Research and Development Co., Ltd.

Layout table for additonal information
Responsible Party: Shanghai Pharmaceuticals Holding Co., Ltd
ClinicalTrials.gov Identifier: NCT03953833     History of Changes
Other Study ID Numbers: CTR20190405
First Posted: May 17, 2019    Key Record Dates
Last Update Posted: May 17, 2019
Last Verified: May 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shanghai Pharmaceuticals Holding Co., Ltd:
DLT
MTD
Safety
tolerability
HER2-positive
Recombinant Humanized Anti-HER2 Monoclonal Antibody

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents